Home | Harrow, Inc.
Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.
About | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …
Harrow Launches VEVYE® Access for All
Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic …
SEC Filings | Harrow, Inc.
Nov 18, 2025 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a …
Leadership | Harrow, Inc.
Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …
In June 2025, Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% for the treatment of post-operative inflammation and …
0001493152-25-012840 | 8-K | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).
News - Harrow, Inc.
Sep 15, 2025 · November 24, 2025 Harrow to Present at Two Investor Conferences in December November 18, 2025 Harrow Announces Closing of Acquisition of Melt Pharmaceuticals …
ImprimisRx Announces Leadership Changes | Harrow, Inc.
Oct 6, 2025 · Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.